Key result
The commercially available DE072 vaccine showed less than 50% protection against a newly identified group of infectious bronchitis viruses, designated as the Georgia 98 serotype.
Population
25 field infectious bronchitis viruses isolated from several states in the United States from 1990 through…
Comparison
Molecular and antigenic examination, cross-virus… vs DE072 serotype and other serotypes of IBV
Design
Preclinical
Authors
Loading...
Suggests limited DE072 cross-protection against Georgia 98 IBV; hypothesis-generating for updated poultry vaccines.
Identification of the Georgia 98 serotype of infectious bronchitis virus and development of an RFLP assay to differentiate it from other serotypes.
Lee et al. (2001) studied Infectious bronchitis virus (n=25). DE072 vaccine was evaluated on Vaccine protection. The commercially available DE072 vaccine showed less than 50% protection against a newly identified group of infectious bronchitis viruses, designated as the Georgia 98 serotype.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: